Target type: molecularfunction
Binding to ceramide 1-phosphate. [GOC:TermGenie, PMID:23863933]
Ceramide 1-phosphate (C1P) binding is a crucial molecular function in various cellular processes, including cell signaling, membrane trafficking, and cell growth and survival. C1P, a bioactive lipid, exerts its effects through interactions with specific protein receptors, known as C1P receptors.
C1P binding initiates a cascade of events that influence downstream signaling pathways. This interaction primarily occurs at the plasma membrane, where C1P receptors are localized. Once C1P binds to its receptor, it triggers a conformational change in the receptor molecule. This conformational change activates the receptor's intracellular signaling domain, leading to the recruitment and activation of downstream signaling molecules.
The specific molecular mechanism of C1P binding and subsequent signaling depends on the type of C1P receptor involved. For instance, the G protein-coupled receptor, GPRC5A, upon binding to C1P, activates the G protein signaling pathway. This pathway involves the activation of various intracellular signaling molecules, such as cyclic AMP (cAMP), phospholipase C (PLC), and protein kinases, ultimately leading to the modulation of cellular functions.
In addition to GPRC5A, other C1P receptors include the sphingosine 1-phosphate (S1P) receptors, which are also G protein-coupled receptors, and the C1P-specific receptor, C1P-R. These receptors, upon binding to C1P, trigger distinct signaling cascades, leading to various cellular responses.
C1P binding is a tightly regulated process, with mechanisms in place to ensure precise control over its activity. These mechanisms include the production and degradation of C1P, the expression and regulation of C1P receptors, and the activity of downstream signaling molecules.
Dysregulation of C1P binding can contribute to various diseases, including cancer, inflammation, and neurodegenerative disorders. Therefore, understanding the molecular function of C1P binding is crucial for developing therapeutic strategies targeting these diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Cytosolic phospholipase A2 | A cytosolic phospholipase A2 that is encoded in the genome of cow. [OMA:A4IFJ5, PRO:DNx] | Bos taurus (cattle) |
Cytosolic phospholipase A2 | A cytosolic phospholipase A2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P47712] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
ici 204,219 | zafirlukast: a leukotriene D4 receptor antagonist | carbamate ester; indoles; N-sulfonylcarboxamide | anti-asthmatic agent; leukotriene antagonist |
arachidonyltrifluoromethane | AACOCF3 : A fatty acid derivative that is arachidonic acid in which the OH part of the carboxy group has been replaced by a trifluoromethyl group arachidonyltrifluoromethane: structure given in first source; inhibits 85-kDa phospholipase A2 | fatty acid derivative; ketone; olefinic compound; organofluorine compound | EC 3.1.1.4 (phospholipase A2) inhibitor |
amentoflavone | biflavonoid; hydroxyflavone; ring assembly | angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite | |
ochnaflavone | ochnaflavone : A biflavonoid with an ether linkage between the B-rings of the apigenin and luteolin subunits. It has been isolated from several members of the Ochnaceae plant family. ochnaflavone: from Lonicera japonica; structure given in first source | aromatic ether; biflavonoid; hydroxyflavone | anti-inflammatory agent; antiatherogenic agent; antibacterial agent; EC 3.1.1.4 (phospholipase A2) inhibitor; leukotriene antagonist; plant metabolite |
efipladib | efipladib: structure in first source | ||
methyl arachidonylfluorophosphonate | phosphonic ester | ||
pyrrophenone | pyrrophenone: structure in first source |